Witjes - Figure 32
MMC vs BCG
FIG. 32: This Figure illustrates an individual patient data meta-analysis of almost 3000 intermediate- and high-risk patients treated with mitomycin or BCG.[17] It showed there is no difference between the two treatments with respect to progression or cancer-specific mortality. The recurrence rate with BCG was lower when it was given as maintenance, but greater when BCG maintenance was not used. Thus, mitomycin appear to be a realistic alternative on the basis of this meta-analysis.
References
Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56:247−56 http://dx.doi.org/10.1016/j.eururo.2009.04.038